Acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography—a subanalysis of the EMPAG-HF trial
Jürgen Bogoviku, Tiến Dũng Nguyễn, Julian Westphal, Pawel Aftanski, Sven Moebius‐Winkler, Franz Haertel, Sissy Grund, Ali Hamadanchi, Martin Busch, P. Christian Schulze
Abstract
BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve prognosis in chronic heart failure as part of currently recommended therapeutic strategies. Transthoracic echocardiography (TTE) is frequently used to assess heart function and dimensions in acute heart failure to lead therapy and assess volume status. Immediate changes, especially of left heart haemodynamic parameters, measured by echocardiography in patients with acute heart failure treated with SGLT2 inhibitors, remain unknown. AIM: The aim of this pre-defined secondary analysis was to assess whether treatment with empagliflozin 25 mg/day in patients with acute heart failure improves echocardiographic parameters of load, left ventricular or right ventricular function. METHODS AND RESULTS: In the single-centre, prospective, double-blind, placebo-controlled EMPAG-HF trial, patients with acute decompensated heart failure (ADHF) were screened and randomized within 12 h following hospital admission to receive either empagliflozin or placebo in addition to standard medical treatment over 5 days. Sixty patients were enrolled and randomized irrespective of left ventricular ejection fraction or diabetes. All patients received 2D TTE on admission (tB = at baseline) and after completing the study treatment (tC = time after completing study medication) (according to study design). The recorded loops were analysed using dedicated software (Image-Arena™ Version 4.6; TomTec Imaging Systems). After 5 days of treatment, patients in the empagliflozin cohort showed a relevant decrease in left atrial volume [LAV: ∆tB-tC = 30.9 ± 27.4; 95% confidence interval (CI) 20.1-41.7) compared to placebo ∆tB-tC = 10.5 ± 26; 95% CI 0.4-20.5; P = <0.001] and left atrial end-systolic volume index (LAESVI: ∆tB-tC = 15.7 ± 15.1; 95% CI 9.8-21.6 vs. placebo ∆tB-tC = 9.7 ± 10.2; 95% CI 5.7-13.6; P = 0.016) compared to placebo. CONCLUSION: Immediate addition of empagliflozin to standard therapy improves echocardiographic parameters of LAV in patients following recompensation of ADHF.